Recent News

• 08.25.2025 - Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
• 08.14.2025 - Cassava Reports Q2 2025 Financials Results and Provides Business Update
• 08.14.2025 - Cassava Reports Q2 2025 Financials Results and Provides Business Update
• 08.07.2025 - Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer
• 08.04.2025 - Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy
• 06.30.2025 - Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting

Recent Filings

• 08.14.2025 - 8-K Current report
• 08.14.2025 - EX-99.1 EX-99.1
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.04.2025 - 8-K Current report
• 08.04.2025 - EX-99.1 EX-99.1
• 07.29.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.16.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 06.30.2025 - EX-99.1 EX-99.1
• 06.30.2025 - 8-K Current report